Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) has received an average recommendation of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $26.25.

Several equities research analysts have commented on the company. Dawson James reissued a “buy” rating on shares of Spring Bank Pharmaceuticals in a report on Monday, August 7th. ValuEngine downgraded Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday. Chardan Capital dropped their target price on Spring Bank Pharmaceuticals from $34.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, August 1st. Cantor Fitzgerald assumed coverage on Spring Bank Pharmaceuticals in a report on Wednesday, July 19th. They issued an “overweight” rating and a $29.00 target price on the stock. Finally, JMP Securities assumed coverage on Spring Bank Pharmaceuticals in a report on Friday, May 19th. They issued a “market perform” rating and a $20.00 target price on the stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.watchlistnews.com/spring-bank-pharmaceuticals-inc-nasdaqsbph-given-average-rating-of-buy-by-analysts/1480449.html.

In other Spring Bank Pharmaceuticals news, Director David Arkowitz purchased 2,500 shares of the stock in a transaction dated Friday, August 4th. The shares were purchased at an average cost of $12.24 per share, with a total value of $30,600.00. Following the completion of the acquisition, the director now directly owns 17,086 shares in the company, valued at approximately $209,132.64. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Kurt M. Eichler purchased 76,923 shares of the stock in a transaction dated Tuesday, June 27th. The shares were acquired at an average cost of $13.00 per share, for a total transaction of $999,999.00. Following the completion of the acquisition, the director now owns 582,533 shares of the company’s stock, valued at $7,572,929. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 81,423 shares of company stock worth $1,055,319. Corporate insiders own 17.60% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in SBPH. C WorldWide Group Holding A S acquired a new position in shares of Spring Bank Pharmaceuticals during the second quarter worth about $340,000. EAM Investors LLC acquired a new position in shares of Spring Bank Pharmaceuticals during the second quarter worth about $578,000. Private Capital Advisors Inc. increased its position in shares of Spring Bank Pharmaceuticals by 50.0% in the second quarter. Private Capital Advisors Inc. now owns 56,250 shares of the company’s stock worth $762,000 after buying an additional 18,750 shares during the last quarter. Vanguard Group Inc. acquired a new position in shares of Spring Bank Pharmaceuticals during the second quarter worth about $794,000. Finally, Morse Asset Management Inc increased its position in shares of Spring Bank Pharmaceuticals by 156.9% in the second quarter. Morse Asset Management Inc now owns 63,700 shares of the company’s stock worth $862,000 after buying an additional 38,900 shares during the last quarter. 9.82% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Spring Bank Pharmaceuticals (NASDAQ SBPH) opened at 11.99 on Friday. Spring Bank Pharmaceuticals has a 12 month low of $6.31 and a 12 month high of $16.97. The stock’s market capitalization is $152.24 million. The stock’s 50 day moving average price is $14.08 and its 200 day moving average price is $11.19.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.

Analyst Recommendations for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.